1 Frueh, FW, Amur, S, Mummaneni, P, Epstein, RS, Aubert, RE, Deluca, TM, Verbrugge, RR, Burckart, GJ, Lesko, LJ. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008, 28: 992–998.
2 Bhatt, DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?. JAMA 2009, 302: 896–897.
3 Eckman, MH, Rosand, J, Greenberg, SM, Gage, BF. Cost‐effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150: 73–83.
4 Woodcock, J, Lesko, LJ. Pharmacogenetics—tailoring treatment for the outliers. N Eng J Med 2009, 360: 811–813.
5 Song, Y, Stampfer, MJ, Liu, S. Meta‐analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004, 141: 137–147.
6 Morgan, TM, Krumholz, HM, Lifton, RP, Spertus, JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large‐scale replication study. JAMA 2007, 297: 1551–1561.
7 Altshuler, D, Daly, MJ, Lander, ES. Genetic mapping in human disease. Science 2008, 322: 881–888.
8 Damani, SB, Topol, EJ. Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007, 50: 1933–1940.
9 Frazer, KA, Ballinger, DG, Cox, DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449: 851–861.
10 Shuldiner, AR, O`Connell, JR, Bliden, KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302: 849–857.
11 Link, E, Parish, S, Armitage, J, et al. SLCO1B1 variants and statin‐induced myopathy—a genomewide study. N Eng J Med 2008, 359: 789–799.
12 Ross, CJ, Katzov‐Eckert, H, Dube, MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009, 41: 1345–1349.
13 Ge, D, Fellay, J, Thompson, AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009, 461: 399–401.
14 Daly, AK, Donaldson, PT, Bhatnagar, P, et al. HLA‐B*5701 genotype is a major determinant of drug‐induced liver injury due to flucloxacillin. Nat Genet 2009, 41: 816–819.
15 Manolio, TA, Collins, FS, Cox, NJ, et al. Finding the missing heritability of complex diseases. Nature 2009, 461: 747–753.
16 Mehta, SR, Yusuf, S, Peters, RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study. Lancet 2001, 358: 527–533.
17 Yusuf, S, Zhao, F, Mehta, SR, Chrolavicius, S, Tognoni, G, Fox, KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Eng J Med 2001, 345: 494–502.
18 Steinhubl, SR, Berger, PB, Mann, JT III
, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288: 2411–2420.
19 Hulot, JS, Bura, A, Villard, E, et al. Cytochrome P450 2C19 loss‐of‐function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108: 2244–2247.
20 Collet, JP, Hulot, JS, Pena, A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373: 309–317.
21 Mega, JL, Close, SL, Wiviott, SD, et al. Cytochrome p‐450 polymorphisms and response to clopidogrel. N Eng J Med 2009, 360: 354–362.
22 Simon, T, Verstuyft, C, Mary‐Krause, M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Eng J Med 2009, 360: 363–375.
23 Sibbing, D, Koch, W, Gebhard, D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel‐treated patients with coronary stent placement. Circulation 121: 512–518.
24 Bonello, L, Camoin‐Jau, L, Armero, S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103: 5–10.
25 Mehta, SR. Current Oasis‐7: benefit to doubling clopidogrel dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Eur Soc Cong 2009.
26 Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2007, 357: 2001–2015.
27 Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009, 361: 1045–1057.
28 Lloyd‐Jones, D, Adams, R, Carnethon, M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119: 480–486.
29 Wysowski, DK, Nourjah, P, Swartz, L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167: 1414–1419.
30 Levine, MN, Raskob, G, Landefeld, S, Kearon, C. Hemorrhagic complications of anticoagulant treatment. Chest 2001, 119: 108S–121S.
31 Moyer, TP, O`Kane, DJ, Baudhuin, LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009, 84: 1079–1094.
32 Rieder, MJ, Reiner, AP, Gage, BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Eng J Med 2005, 352: 2285–2293.
33 Klein, TE, Altman, RB, Eriksson, N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Eng J Med 2009, 360: 753–764.
34 Epstein, RS, Moyer, TP, Aubert, RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM‐WES (Medco‐Mayo warfarin effectiveness study). J Am Coll Cardiol.
35 Eriksson, BI, Dahl, OE, Rosencher, N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet 2007, 370: 949–956.
36 Bristow, M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003, 107: 1100–1102.
37 Bristow, MR. Beta‐adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101: 558–569.
38 Kaye, DM, Lefkovits, J, Jennings, GL, Bergin, P, Broughton, A, Esler, MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26: 1257–1263.
39 Shekelle, PG, Rich, MW, Morton, SC, et al. Efficacy of angiotensin‐converting enzyme inhibitors and beta‐blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta‐analysis of major clinical trials. J Am Coll Cardiol 2003, 41: 1529–1538.
40 Liggett, SB, Mialet‐Perez, J, Thaneemit‐Chen, S, et al. A polymorphism within a conserved beta(1)‐adrenergic receptor motif alters cardiac function and beta‐blocker response in human heart failure. Proc Natl Acad Sci USA 2006, 103: 11288–11293.
41 Liggett, SB, Cresci, S, Kelly, RJ, et al. A GRK5 polymorphism that inhibits beta‐adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14: 510–517.
42 Kohout, TA, Lefkowitz, RJ. Regulation of G protein‐coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003, 63: 9–18.
43 Dallongeville, J, Lussier‐Cacan, S, Davignon, J. Modulation of plasma triglyceride levels by apoE phenotype: a meta‐analysis. J Lipid Res 1992, 33: 447–454.
44 Davignon, J, Cohn, JS, Mabile, L, Bernier, L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999, 286: 115–143.
45 Eichner, JE, Dunn, ST, Perveen, G, Thompson, DM, Stewart, KE, Stroehla, BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002, 155: 487–495.
46 Ordovas, JM, Schaefer, EJ. Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the APOE gene. Br J Nutr 2000, 83: S127–S136.
47 Davignon, J, Gregg, RE, Sing, CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8: 1–21.
48 Kathiresan, S, Willer, CJ, Peloso, GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41: 56–65.
49 Gerdes, LU, Gerdes, C, Kervinen, K, et al. The apolipo‐ protein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000, 101: 1366–1371.
50 Shiffman, D, Chasman, DI, Zee, RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women`s Health Study. J Am Coll Cardiol 2008, 51: 444–448.
51 Iakoubova, OA, Tong, CH, Rowland, CM, et al. Association of the Trp719Arg polymorphism in kinesin‐like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51: 435–443.
52 Iakoubova, OA, Sabatine, MS, Rowland, CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT‐TIMI 22 study. J Am Coll Cardiol 2008, 51: 449–455.
53 Statin Check
. Berkely HeartLab Inc.
54 Wellcome Trust Case Control Consortium. Genome‐wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447: 661–678.
55 Hauser, ER, Crossman, DC, Granger, CB, et al. A ge‐ nomewide scan for early‐onset coronary artery disease in 438 families: the GENECARD study. Am J Hum Genet 2004, 75: 436–47.
56 Helgadottir, A, Thorleifsson, G, Manolescu, A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316: 1491–1493.
57 Kathiresan, S, Melander, O, Guiducci, C, et al. Six new loci associated with blood low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40: 189–197.
58 McPherson, R, Pertsemlidis, A, Kavaslar, N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316: 1488–1491.
59 Samani, NJ, Erdmann, J, Hall, AS, et al. Genomewide association analysis of coronary artery disease. N Eng J Med 2007, 357: 443–453.
60 Erdmann, J, Grosshennig, A, Braund, PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009, 41: 280–282.
61 Kathiresan, S, Voight, BF, Purcell, S, et al. Genome‐wide association of early‐onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41: 334–341.
62 Marian, AJ. Surprises of the genome and “personalized” medicine. J Am Coll Cardiol 2008, 51: 456–458.
63 Iakoubova, O, Shepherd, J, Sacks, F. Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy. J Am Coll Cardiol 2008, 51: 2195–2196.
64 Konig, J, Seithel, A, Gradhand, U, Fromm, MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372: 432–443.
65 Voora, D, Shah, SH, Spasojevic, I, et al. The SLCO1B1*5 genetic variant is associated with statin‐induced side effects. J Am Coll Cardiol 2009, 54: 1609–1616.